L
3.38
0.09 (2.74%)
| Penutupan Terdahulu | 3.29 |
| Buka | 3.25 |
| Jumlah Dagangan | 723,333 |
| Purata Dagangan (3B) | 2,563,859 |
| Modal Pasaran | 289,295,520 |
| Harga / Buku (P/B) | 2.18 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| EPS Cair (TTM) | -1.51 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.37% |
| Nisbah Semasa (MRQ) | 7.48 |
| Aliran Tunai Operasi (OCF TTM) | -86.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.86 M |
| Pulangan Atas Aset (ROA TTM) | -31.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Larimar Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
0.9
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.88 |
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.43% |
| % Dimiliki oleh Institusi | 103.11% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 21.00 (Oppenheimer, 521.30%) | Beli |
| Median | 11.00 (225.44%) | |
| Rendah | 7.00 (Baird, 107.10%) | Beli |
| Purata | 13.00 (284.62%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 3.58 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Oppenheimer | 02 Oct 2025 | 21.00 (521.30%) | Beli | 4.28 |
| Baird | 30 Sep 2025 | 7.00 (107.10%) | Beli | 3.23 |
| Wedbush | 30 Sep 2025 | 11.00 (225.44%) | Beli | 3.23 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Nov 2025 | Pengumuman | Larimar Therapeutics Reports Third Quarter 2025 Financial Results |
| 29 Sep 2025 | Pengumuman | Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia |
| 28 Sep 2025 | Pengumuman | Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |